Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 1,208 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study Powder Clear all

Conditions: Breast Cancer, Vaginal Dryness, Dyspareunia, Sexual Health Quality of Life
Interventions: Testosterone; Drug
Lead sponsor: Creighton University; Other
Eligibility: 50 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Parainfluenza
Interventions: DAS181 dry powder, formulation F02, Lactose Placebo; Drug
Lead sponsor: Ansun Biopharma, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 45
States / cities: Phoenix, Arizona • Duarte, California • Orange, California + 33 more

Conditions: Microbiome
Interventions: strawberry powder, placebo powder; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Fluticasone Propionate/Formoterol Fumarate, Fluticasone Propionate, Formoterol Fumarate, Fluticasone Propionate/Salmeterol Xinafoate, Placebo; Drug
Lead sponsor: Dey; Industry
Eligibility: 40 Years and older
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 49
States / cities: Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 44 more

Conditions: Safety, and Tolerability
Interventions: DHE inhalation powder low dose administered via dry powder inhaler (DPI) device, DHE inhalation powder high dose administered via dry powder inhaler (DPI) device, DHE injected intravenously (1 mg), DHE 2 mg administered by nasal spray (Migranal®), Metoclopramide 10mg; Combination Product · Drug
Lead sponsor: Aspeya Switzerland SA; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Hypertrophic Scar
Interventions: STP705, Placebo; Drug
Lead sponsor: Sirnaomics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cypress, California

Conditions: Sphingomyelin Lipidosis
Interventions: placebo (saline), Olipudase alfa; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2023
U.S. locations: 3
States / cities: San Francisco, California • Decatur, Georgia • The Bronx, New York

Conditions: PreDiabetes, Metabolic Syndrome
Interventions: Freeze-dried strawberry powder; Drug
Lead sponsor: University of Nevada, Las Vegas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Heartburn, Acid Regurgitation
Interventions: Gastro-AD®, Placebo; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 60 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Pulmonary Hypertension Associated With Interstitial Lung Disease
Interventions: Placebo, Seralutinib, Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: GB002, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Fresno, California • Albuquerque, New Mexico • Richmond, Virginia

Conditions: New Daily Persistent Headache (NDPH)
Interventions: Naltrexone HCl (Bulk) Powder; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 10 Years to 17 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Burn
Interventions: Aquacel AG, typical carboxymethylcellulose dressing, Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing; Device
Lead sponsor: ULURU Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: NVA237 100 µg, Placebo, NVA237 200 µg; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 16
States / cities: Glendale, Arizona • Phoenix, Arizona • Wheat Ridge, Colorado + 12 more

Conditions: Chronic Obstructive Pulmonary Disease COPD
Interventions: Glycopyrronium/Formoterol Fumarate, umeclidinium/vilanterol; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 95 Years
Enrollment: 1,119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 15
States / cities: Tempe, Arizona • Escondido, California • Sacramento, California + 12 more

Conditions: Anxiety, Generalized Anxiety Disorder
Interventions: Cannabidiol (CBD)- containing consumer products; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 24 Years to 44 Years · Female only
Enrollment: 1,350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hunger
Interventions: psyllium fiber 6.8g, placebo; Dietary Supplement
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Tinnitus
Interventions: Oxytocin, Placebo nasal spray; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: Lebrikizumab, Placebo, Standard of Care; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 16
States / cities: Mission Viejo, California • Stockton, California • Aurora, Colorado + 12 more

Conditions: Long COVID-19 Syndrome
Interventions: Low carbohydrate diet intervention; Dietary Supplement
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Essential Tremor of the Upper Limb
Interventions: NT 201, Placebo; Drug
Lead sponsor: Merz Pharmaceuticals GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 9
States / cities: Tampa, Florida • Omaha, Nebraska • Las Vegas, Nevada + 6 more

Conditions: Organophosphorus Poisoning
Interventions: atropine sulfate; Drug
Lead sponsor: MicroDose Defense Products L.L.C.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium/Salmeterol, Salmeterol, Placebo, Tiotropium; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 16
States / cities: Anniston, Alabama • Mobile, Alabama • Clearwater, Florida + 10 more

Conditions: Infections, Bacterial
Interventions: GSK1322322 (mesylate salt) Powder for Injection, GSK1322322 (freebase) tablets, GSK1322322 (mesylate salt) Powder for Oral Solution, GSK1322322 (freebase) tablets FED; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Aging, Sarcopenia
Interventions: Peanut Protein Powder, Full body resistance training; Dietary Supplement · Behavioral
Lead sponsor: Auburn University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Auburn, Alabama

Search by objective public record fields.

Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen

Effect of Strawberry Consumption on the Microbiome

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults

A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar

Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

Strawberries and Risk of Diabetes in Adults

Fermented Soy and Heartburn Symptom Relief

Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children

Altrazeal Range of Motion Study Comparing With Typical Carboxymethyl

Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Evaluation of Effects of CBD Products on Anxiety Among U.S. Women

Study of Psyllium 6.8 g Versus Placebo on Satiety in Healthy Volunteers

High Dose Oxytocin Nasal Spray for Treatment of Tinnitus

A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Long COVID-19 Syndrome Lifestyle Intervention Study

A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm

A Study of Inhaled Atropine Sulfate in Healthy Adults

Tiotropium/Salmeterol Inhalation Powder in COPD

A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy Subjects

Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults